The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandem...
Dent, S;
Brezden-Masley, C;
Clarke, B;
Davis, MK;
Jassal, DS;
Johnson, C;
Lemieux, J;
Paterson, I;
Sebag, IA;
Simmons, C;
Sulpher, J;
Thain, K;
Thavendiranathan, P;
Wentzell, JR;
Wurtele, N;
Côté, MA;
Fine, NM;
Haddad, H;
Hayley, BD;
Hopkins, S;
Joy, AA;
Rayson, D;
Stadnick, E;
Straatman, L;
Virani, SA.
Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This ...
Antineoplásicos,
Biomarcadores,
Cardiotónicos,
Cardiotoxinas,
Troponina T,
Péptido Natriurético Encefálico,
Proteína C-Reactiva,
Antineoplásicos/efectos adversos,
Arritmias Cardíacas,
Cardiotoxicidad,
Trombosis Coronaria,
Diagnóstico Precoz,
Ecocardiografía Tridimensional,
Hipertensión/terapia,
Imagen por Resonancia Cinemagnética,
Isquemia Miocárdica,
Péptido Natriurético Encefálico,
Neoplasias/terapia,
Prevención Primaria,
Radioterapia,
Factores de Riesgo,
Disfunción Ventricular Izquierda,
Antineoplásicos/efectos adversos,
Cardiotoxicidad/diagnóstico,
Cardiotoxinas/efectos adversos,
Radioterapia/efectos adversos
Zinzani, Pier Luigi;
Marchetti, Monia;
Billio, Atto;
Barosi, Giovanni;
Carella, Angelo Michele;
Lazzarino, Mario;
Martelli, Maurizio;
Rambaldi, Alessandro;
Rigacci, Luigi;
Tarella, Corrado;
Vitolo, Umberto;
Tura, Sante.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
Anticuerpos Monoclonales,
Anticuerpos,
Anticuerpos Monoclonales de Origen Murino/uso terapéutico,
Antineoplásicos,
Esquema de Medicación,
Trasplante de Células Madre Hematopoyéticas,
Linfoma Folicular/patología,
Linfoma/terapia,
Estadificación de Neoplasias,
Rituximab,
Factores de Tiempo